Filing Details
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) filed a Form 8-K with the Securities and Exchange Commission on November 06, 2026, disclosing a material event.
8k filedNASDAQ:ACRV
Acrivon Therapeutics, Inc. (ACRV) Reports Material Event to SEC
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) filed a Form 8-K with the Securities and Exchange Commission on November 06, 2026, disclosing a material event.
At publication ·
What changed
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Acrivon Therapeutics filed a Form 8-K on November 6, 2026, disclosing a material event to shareholders.
- The company's stock trades at $1.57 with a market capitalization of $47.6 million.
- Material events reported in 8-K filings can include leadership changes, acquisitions, asset sales, or financial guidance updates.
Market Context
Acrivon Therapeutics, Inc.'s stock currently trades at $1.57 with a market capitalization of $47.6M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Acrivon Therapeutics, Inc.'s stock.
All SEC filings for Acrivon Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ACRV Stock Page
Frequently Asked Questions
Where can I read ACRV's SEC filings?
Browse all filings on our ACRV SEC filings page.
What types of SEC filings does Acrivon Therapeutics, Inc. file?
Public companies like Acrivon Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.